Kyle Dempsey
Directeur/Bestuurslid bij OPTINOSE, INC.
Vermogen: 6 089 $ op 30-04-2024
Actieve functies van Kyle Dempsey
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| OPTINOSE, INC. | Directeur/Bestuurslid | 10-12-2021 | - |
| Independent Dir/Board Member | 10-12-2021 | - | |
| HLS THERAPEUTICS INC. | Directeur/Bestuurslid | 29-11-2022 | - |
| Independent Dir/Board Member | 29-11-2022 | - | |
| MVM Partners LLC | Private Equity Investor | 01-09-2017 | - |
GT Medical Technologies, Inc.
 GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Directeur/Bestuurslid | - | - |
Loopbaan van Kyle Dempsey
Opleiding van Kyle Dempsey
| Harvard Medical School | Doctorate Degree |
| Bowdoin College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 7 |
| Canada | 2 |
Operationeel
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Private Equity Investor | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 4 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| HLS THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| MVM Partners LLC | Finance |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Health Technology |
- Beurs
- Insiders
- Kyle Dempsey
- Ervaring
